Mandate

Vinge advises Vicore Pharma in connection with a directed share issue

December 04, 2018

The board of directors of Vicore Pharma has resolved, subject to the approval by an extraordinary general meeting, on a directed new issue of shares, whereby Vicore Pharma will raise proceeds of approximately SEK 160 million before issue costs. 

The share issue is directed to a number of selected Swedish and international long-term institutional investors and sector specialist funds, on the basis of a book building procedure conducted by DNB Markets, goetzpartners securities and Zonda Partners.

Vicore Pharma is a Swedish rare disease company focused on interstitial lung diseases and related indications. The company’s shares are admitted to trading on Nasdaq First North. 

Vinge’s team has consisted of Jesper Schönbeck, Johan Winnerblad, Nils Fredrik Dehlin, Amanda Knutsson and Emelie Svanberg.

Vinge top ranked within intellectual property law

Vinge’s IP practice group is once again top ranked in IAM’s annual ranking Patent 1000. Håkan Borgenhäll, Malin Malm Waerme and Stojan Arnerstål also receive individual recommendations.
July 06, 2022

New Regulation on foreign subsidies – the Council and the EP has reached an agreement

On 30 June, the Council and the European Parliament reached a provisional political agreement on a new Foreign Subsidies Regulation, based on a proposal by the Commission of 5 May 2021.
July 05, 2022

New partners and counsel appointed at Vinge’s Malmö and Stockholm offices

Advokat Daniel Daun and advokat Victor Ericsson at Vinge’s Malmö and Stockholm offices respectively have been appointed as new partners as of 1 January 2023. Jacob Jeanrond, Caroline Krassén, Henrik Schön, Maria Dahlin Kolvik, Sara Strandberg and Linn Adelwald have been elected as counsel at Vinge’s Stockholm office.
June 30, 2022